GNLX

#3925
Genelux Corporation Common Stock
2.64 USD
+4.35%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
2.64
2.64
Rango anual
2.25
8.54
Cambio diario
+4.35%
Variación mensual
0.00%
Variación en los últimos 6 meses
-50.00%
Cambio anual
+5.18%
Cierres anteriores
2.53
Abrir
2.64
Bid
Ask
Mínimo
2.64
High
2.64
Volumen
9
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 118.29 M
  • Employee 26
  • Founded 2001
  • CEO N/A
  • Website www.genelux.com
  • Headquarter Delaware, United States
  • FIGI BBG0044BNBX6
  • Industry Technology
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
-5.07
Relación precio/flujo de caja
20.26 K

Genelux Corporation

Genelux Corporation is a publicly traded late clinical-stage company developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity. The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME.

Noticias